The resulting increase in data required for transmission, storage and communication multiplies exponentially compared with
The digital factory model, when applied to these and similar
situations within logistics service provider facilities and other
warehouses, will recommend improvements in processes and
procedures to compensate for the side effects from DSCSA compliance. By approaching the warehouse layout, material handling
equipment and personnel with similar technology employed on
the packaging lines, hidden patterns emerge from evaluation of
data that will suggest changes in the three key areas of warehouse management—time, touch and travel—to compensate for
The final psychological state of serialization—acceptance and
renewal—is not an end in itself. The combination of technological advancement performance enhancement at this stage calls for
continuous process improvement for all parties to succeed within
the DSCSA-compliant pharmaceutical supply chain.
For manufacturers still passing through the initial stages of
serialization, the road ahead may seem insurmountable. Remain
committed to the process. Acceptance and renewal, the final
stage on your serialization journey, is attainable.
The acceptance represents the understanding that DSCSA
The renewal arises from the knowledge that new options ex-
ist in the digital factory and digital warehouse that transform
the capital investment for serialization compliance into a leaner,
more efficient and more profitable production environment. CP
1. Souza, Chris. “Serialization Readiness: Takeaways from 2016 Pharmaceutical Serialization & Traceability Report.” Track Trace Rx. Rx Trace, 22 Mar.
2017. Web. 12 July 2017. < http://blog.tracktracerx.com/serialization-read-
2. Rodgers, Dirk. “Will President Trump Eliminate The DSCSA? – Rx Trace.”
Rx Trace. Rx Trace, 09 Nov. 2016. Web. 12 July 2017. <https://www.rxtrace.
3. Editors, Pharmaceutical Technology. “Technology Selection Marked as the
Biggest Hurdle in Serialization Compliance.” Pardon Our Interruption.
Pharmaceutical Technology, 26 June 2017. Web. 12 July 2017. <http://
4. Basta, Nicholas. “2017 Product Security Report.” Pharmaceutical Commerce.
Pharmaceutical Commerce, 18 May 2017. Web. 12 July 2017. <http://
With more than 100 years of combined experience in the industry
specilizing in contract manufacturing, packaging and labratory services,
ACP is at your service today.
The safe manufacturing of products containing potent active
pharmaceutical a ingredients (APIs) requires both “hardware” – facility
features, equiment and engineering controls – and “software” – practices
and procedures to adequately protect personnel and the environment,
including the facility. With this in mind, ACP has built segregated ISO 7 and
ISO 8 clean room suites with dedicated air handling for potent compounds.
ACP has a state of the art analytical labratory. With a full range of
pharmaceutical and nutritional supplement testing capabilities, our
experienced xpe e team is flexible and ready to meet your needs. Let your project
define what service model works best for you.
Contact: Steve Schweibenz, President
+1 215.256.5920 firstname.lastname@example.org